We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Shuttle Pharmaceuticals Holdings Inc (SHPH) USD0.00001

Sell:$0.41 Buy:$0.42 Change: $0.004743 (1.12%)
Market closed |  Prices as at close on 10 May 2024 | Switch to live prices |
Sell:$0.41
Buy:$0.42
Change: $0.004743 (1.12%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 10 May 2024 | Switch to live prices |
Sell:$0.41
Buy:$0.42
Change: $0.004743 (1.12%)
Market closed |  Prices as at close on 10 May 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.

Contact details

Address:
401 Professional Drive, Suite 260
GAITHERSBURG
20879
United States
Telephone:
+1 (240) 4034212
Website:
https://shuttlepharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SHPH
ISIN:
US8256932034
Market cap:
$7.02 million
Shares in issue:
16.79 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Anatoly Dritschilo
    Chairman of the Board, Chief Executive Officer
  • Peter Dritschilo
    President, Chief Operating Officer
  • Michael Vander Hoek
    Chief Financial Officer, Vice President - Operations and Regulatory
  • Mira Jung
    Chief Scientific Officer - Biology
  • Tyvin Rich
    Chief Medical Officer, Chief Clinical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.